New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: Acute effects of female hormones on cardiac ion channels and cardiac repolarization

Journal of Pharmacological Sciences

Volumn 109, Issue 3, 2009, Pages 334-340

  Kurokawa, Junko ^a   Suzuki, Takeshi ^b   Furukawa, Tetsushi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Arrhythmia; Cardiac disease; Cardiac ion channel; Gender difference; Menstrual cycle; Sex hormone

Indexed keywords

DOFETILIDE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; IBUTILIDE; ION CHANNEL; PHOSPHATIDYLINOSITOL 3 KINASE; POTASSIUM CHANNEL HERG; PROGESTERONE; PROGESTERONE RECEPTOR; TESTOSTERONE;

CARDIOVASCULAR RISK; DRUG BINDING; ENZYME ACTIVATION; ENZYME REGULATION; HEART ARRHYTHMIA; HEART MUSCLE; HEART REPOLARIZATION; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; MENSTRUAL CYCLE; NONHUMAN; PROGESTERONE BLOOD LEVEL; PROTEIN EXPRESSION; QT PROLONGATION; SEX DIFFERENCE; SHORT SURVEY; TORSADE DES POINTES;

ESTROGENS; FEMALE; HUMANS; ION CHANNELS; LONG QT SYNDROME; MALE; MENSTRUAL CYCLE; MYOCARDIUM; PROGESTERONE; RISK FACTORS; SEX CHARACTERISTICS;

EID: 67249120468     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08R23FM     Document Type: Short Survey

References (50)

1. Lehmann MH, Hardy S, Archibald D, quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation. 1996;94:2535-2541.
2. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-2597.
3. Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. JAMA. 1998; 280:1774-1776.
4. Tamargo J. Drug-induced torsade de pointes: from molecular biology to bedside. Jpn J Pharmacol. 2000;83:1-19.
5. Hashimoto K. Arrhythmia models for drug research: classification of antiarrhythmic drugs. J Pharmacol Sci. 2007;103:333-346.
6. James AF, Choisy SC, Hancox JC. Recent advances in understanding sex differences in cardiac repolarization. Prog Biophys Mol Biol. 2007; 94:265-319.
7. Hreiche R, Morissette P, Turgeon J. Drug-induced long QT syndrome in women: review of current evidence and remaining gaps. Gend Med. 2008;5:124-135.
8. Fermini B, Fossa AA. The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Rev Drug Discovery. 2003;2:439-447.
9. Abriel H, Schlapfer J, Keller DI, Gavillet B, Buclin T, Biollaz J, et al. Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy. Swiss Med Wkly. 2004;134:685-694.
10. Marx SO, Kurokawa J, Reiken S, Motoike H, D'Armiento J, Marks AR, et al. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1- KCNE1 potassium channel. Science. 2002;295:496-499. (Pubitemid 34101639)
11. Kurokawa J. Compartmentalized regulations of ion channels in the heart. Biol Pharm Bull. 2007;30:2231-2237.
12. Satoh Y, Sugiyama A, Tamura K, Hashimoto K. Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: potential utility of mexiletine for the treatment of drug-induced long QT syndrome. Jpn J Pharmacol. 2000;83:327-334.
13. Takahara A, Nakamura H, Nouchi H, Tamura T, Tanaka T, Shimada H, et al. Analysis of arrhythmogenic profile in a canine model of chronic atrioventricular block by comparing in vitro effects of the class III antiarrhythmic drug nifekalant on the ventricular action potential indices between normal heart and atrioventricular block heart. J Pharmacol Sci. 2007;103:181-188. (Pubitemid 46294650)
14. Locati EH, Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Lehmann MH, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS registry. Circulation. 1998;97:2237-2244.
15. Bazett HC. The time relations of the blood-pressure changes after excision of the adrenal glands, with some observations on blood volume changes. J Physiol. 1920;53:320-339.
16. Bidoggia H, Maciel JP, Capalozza N, Mosca S, Blaksley EJ, Valverde E, et al. Sex differences on the electrocardiographic pattern of cardiac repolarization: possible role of testosterone. Am Heart J. 2000;140:678-683.
17. Abi-Gerges N, Philp K, Pollard C, Wakefield I, Hammond TG, Valentin JP. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes. Fundam Clin Pharmacol. 2004;18:139-151.
18. Bai CX, Kurokawa J, Tamagawa M, Nakaya H, Furukawa T. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation. 2005;112:1701-1710.
19. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation. 1996;94:1471-1474.
20. Pham TV, Sosunov EA, Gainullin RZ, Danilo P Jr, Rosen MR. Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by IK- blocking drugs. Circulation. 2001;103:2207-2212.
21. Hulot J-S, Demolis J-L, Riviere R, Strabach S, Christin-Maitre S, Funck-Brentano C. Influence of endogenous oestrogens on QT interval duration. Eur Heart J. 2003;24:1663-1667.
22. Merri M, Benhorin J, Alberti M, Locati E, Moss AJ. Electro- cardiographic quantitation of ventricular repolarization. Circulation. 1989;80:1301-1308.
23. Rautaharju PM, Zhou SH, Wong S, Calhoun HP, Berenson GS, Prineas R, et al. Sex differences in the evolution of the electro- cardiographic QT interval with age. Can J Cardiol. 1992;8:690-695.
24. Stramba-Badiale M, Spagnolo D, Bosi G, Schwartz PJ. Are gender differences in QTc present at birth? MISNES Investigators. Multicenter Italian Study on Neonatal Electro- cardiography and Sudden Infant Death Syndrome. Am J Cardiol. 1995;75:1277-1278.
25. Furukawa T, Bai CX, Kaihara A, Ozaki E, Kawano T, Nakaya Y, et al. Ginsenoside Re, a main phytosterol of Panax ginseng, activates cardiac potassium channels via a nongenomic pathway of sex hormones. Mol Pharmacol. 2006;70:1916-1924.
26. Kurokawa J, Furukawa T. [Protein modification of cardiac potassium channels and lethal arrhythmias.] Folia Pharmacol Jpn (Nippon Yakurigaku Zasshi). 2005;26:273-279. (in Japanese)
27. Kadish AH, Greenland P, Limacher MC, Frishman WH, Daugherty SA, Schwartz JB. Estrogen and progestin use and the QT interval in postmenopausal women. Ann Noninvasive Electrocardiol. 2004;9:366-374.
28. Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in women during the menstrual cycle. JAMA. 2001;285:1322-1326.
29. Burke JH, Ehlert FA, Kruse JT, Parker MA, Goldberger JJ, Kadish AH. Gender-specific differences in the QT interval and the effect of autonomic tone and menstrual cycle in healthy adults. Am J Cardiol. 1997;79:178-181.
30. Nakagawa M, Ooie T, Takahashi N, Taniguchi Y, Anan F, Yonemochi H, et al. Influence of menstrual cycle on QT interval dynamics. Pacing Cclin Electrophysiol. 2006;29:607-613. (Pubitemid 43886612)
31. Rashba EJ, Zareba W, Moss AJ, Hall WJ, Robinson J, Locati EH, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. Circulation. 1998; 97:451-456. (Pubitemid 28090216)
32. Furukawa T, Kurokawa J. Regulation of cardiac ion channels via non-genomic action of sex steroid hormones: Implication for the gender difference in cardiac arrhythmias. Pharmacol Ther. 2007;115:106-115.
33. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev. 2001;81:1269-1304.
34. Song M, Helguera G, Eghbali M, Zhu N, Zarei MM, Olcese R, et al. Remodeling of Kv4.3 potassium channel gene expression under the control of sex hormones. J Biol Chem. 2001;276:31883-31890. (Pubitemid 37384842)
35. Helguera G, Olcese R, Song M, Toro L, Stefani E. Tissue- specific regulation of Ca2+ channel protein expression by sex hormones. Biochim Biophys Acta. 2002;1569:59-66.
36. Nakamura H, Kurokawa J, Bai CX, Asada K, Xu J, Oren RV, et al. Progesterone regulates cardiac repolarization through a nongenomic pathway: an in vitro patch-clamp and computational modeling study. Circulation. 2007;116:2913-2922.
37. Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol. 2003;148:281-292.
38. Ehring GR, Kerschbaum HH, Eder C, Neben AL, Fanger CM, Khoury RM, et al. A nongenomic mechanism for progesterone- mediated immunosuppression: inhibition of K+ channels, Ca2+ signaling, and gene expression in T lymphocytes. J Exp Med. 1998;188:1593-1602.
39. Mendiberri J, Rauschemberger MB, Selles J, Massheimer V. Involvement of phosphoinositide-3-kinase and phospholipase C transduction systems in the non-genomic action of progesterone in vascular tissue. Int J Biochem Cell Biol. 2006;38:288-296.
40. Fischmeister R, Castro L, Abi-Gerges A, Rochais F, Vandecasteele G. Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol A Mol Integr Physiol. 2005;142:136-143.
41. Kass RS, Kurokawa J, Marx SO, Marks AR. Leucine/isoleucine zipper coordination of ion channel macromolecular signaling complexes in the heart. Roles in inherited arrhythmias. Trends Cardiovasc Med. 2003;13:52-56.
42. Janse de Jonge XA, Boot CR, Thom JM, Ruell PA, Thompson MW. The influence of menstrual cycle phase on skeletal muscle contractile characteristics in humans. J Physiol. 2001;530:161-166.
43. Faber GM, Rudy Y. Action potential and contractility changes in [Na+]i overloaded cardiac myocytes: a simulation study. Biophys J. 2000;78:2392-2404.
44. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008;88:581-609.
45. Hara M, Danilo P Jr, Rosen MR. Effects of gonadal steroids on ventricular repolarization and on the response to E4031. J Pharmacol Exp Ther. 1998;285:1068-1072.
46. Fulop L, Banyasz T, Szabo G, Toth IB, Biro T, Lorincz I, et al. Effects of sex hormones on ECG parameters and expression of cardiac ion channels in dogs. Acta Physiol (Oxf). 2006;188:163-171. (Pubitemid 44622364)
47. Kurokawa J, Tamagawa M, Harada N, Honda SI, Bai CX, Nakaya H, et al. Acute effects of estrogen on the guinea pig and human IKl channels and drug-induced prolongation of cardiac repolarization. J Physiol. 2008;586:2961-2973.
48. Kakusaka S, Asayama M, Kaihara A, Sasano T, Suzuki T, Kurokawa J, et al. A receptor-independent effect of estrone sulfate on the hERG channel. J Pharmacol Sci. 2009;109:152-156.
49. Sanguinetti MC, Mitcheson JS. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci. 2005;26:119-124.
50. Clancy CE, Kurokawa J, Tateyama M, Wehrens XH, Kass RS. K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation. Annu Rev Pharmacol Toxicol. 2003;43:441-461.